- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Outer nuclear layer.
Displaying page 1 of 1.
EudraCT Number: 2018-003500-40 | Sponsor Protocol Number: PQ-110-002 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: An Open-Label Extension Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of QR-110 in Subjects with Leber Congenital Amaurosis (LCA) due to the C.2991+1655a>G Mutation (P.... | |||||||||||||
Medical condition: Leber Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004783-35 | Sponsor Protocol Number: OPH2005 | Start Date*: 2018-07-10 | |||||||||||
Sponsor Name:IVERIC bio | |||||||||||||
Full Title: A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease | |||||||||||||
Medical condition: Autosomal Recessive Stargardt Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003501-25 | Sponsor Protocol Number: PQ-110-003 | Start Date*: 2019-02-28 | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due t... | |||||||||||||
Medical condition: Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001874-32 | Sponsor Protocol Number: RDC-CNGA3-01 | Start Date*: 2015-09-09 | |||||||||||
Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
Full Title: Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observe... | |||||||||||||
Medical condition: CNGA3-linked achromatopsia | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001496-20 | Sponsor Protocol Number: SMR3438 | Start Date*: 2019-05-14 | |||||||||||
Sponsor Name:Katairo GmbH | |||||||||||||
Full Title: A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease | |||||||||||||
Medical condition: Stargardt Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002433-38 | Sponsor Protocol Number: PQ-421a-001 | Start Date*: 2019-02-15 | |||||||||||
Sponsor Name:ProQR Therapeutics | |||||||||||||
Full Title: A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
Medical condition: Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000457-53 | Sponsor Protocol Number: STREAM | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:CECS/I-STEM | |||||||||||||
Full Title: A phase 1/2, open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) i... | |||||||||||||
Medical condition: Retinitis Pigmentosa due to monogenic mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004547-77 | Sponsor Protocol Number: RN03-CP-0001 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:ReNeuron Ltd | |||||||||||||
Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP) | |||||||||||||
Medical condition: Retinitis Pigmentosa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000813-22 | Sponsor Protocol Number: PQ-110-001 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:ProQR Therapeutics | |||||||||||||
Full Title: An Open-Label, Single Arm, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation ... | |||||||||||||
Medical condition: Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003498-82 | Sponsor Protocol Number: 4429-301 | Start Date*: 2019-03-18 | |||||||||||
Sponsor Name:Acucela Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease | |||||||||||||
Medical condition: Stargardt Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DK (Completed) DE (Completed) ES (Ongoing) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000239-34 | Sponsor Protocol Number: PONTIACII | Start Date*: 2015-12-30 |
Sponsor Name:Medizinische Universität Wien | ||
Full Title: NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial | ||
Medical condition: The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population o... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
